Dyne Therapeutics (NASDAQ:DYN) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.88) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.04, Zacks reports.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN traded down $1.29 during midday trading on Monday, hitting $12.32. 2,162,888 shares of the company's stock were exchanged, compared to its average volume of 2,264,419. The firm's fifty day simple moving average is $16.98 and its 200-day simple moving average is $27.50. The company has a market cap of $1.25 billion, a PE ratio of -3.46 and a beta of 1.11. Dyne Therapeutics has a twelve month low of $12.28 and a twelve month high of $47.45.

Insider Buying and Selling at Dyne Therapeutics

In related news, SVP Richard William Scalzo sold 1,455 shares of the company's stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the completion of the sale, the senior vice president now directly owns 127,078 shares of the company's stock, valued at $3,573,433.36. This represents a 1.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $65,632.08. Following the transaction, the insider now directly owns 201,685 shares in the company, valued at approximately $5,671,382.20. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,387 shares of company stock worth $142,789 over the last three months. Insiders own 20.77% of the company's stock.

Wall Street Analyst Weigh In

DYN has been the subject of a number of research analyst reports. Guggenheim restated a "buy" rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Baird R W raised shares of Dyne Therapeutics to a "strong-buy" rating in a research note on Thursday, December 12th. Chardan Capital reaffirmed a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Friday. Royal Bank of Canada reissued an "outperform" rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Finally, Raymond James upgraded Dyne Therapeutics to a "strong-buy" rating in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $48.64.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.